Drugs News and Research

RSS

$Lenvatinib therapy improves survival in patients with advanced radioiodine-refractory thyroid cancer$

Lenvatinib therapy improves survival in patients with advanced radioiodine-refractory thyroid cancer

In a pivotal Phase III study led by researchers at The University of Texas MD Anderson Cancer Center, the oral anti-angiogenic therapy lenvatinib has shown dramatic improvement in progression-free survival in patients with advanced radioiodine-refractory thyroid cancer.

12 Feb 2015

Specific combinations of therapies kill cancer cells, reduce tumors

Controlling the time and sequence of cancer therapies may hold the key to unlocking better outcomes for patients with aggressive cancers, according to research published today.

12 Feb 2015

Understanding the pattern of cellular changes that lead to retinal ganglion cell death in glaucoma

Glaucoma, the second leading cause of blindness, usually stems from elevated eye pressure, which in turn damages and destroys specialized neurons in the eye known as retinal ganglion cells. To better understand these cellular changes and how they influence the progression and severity of glaucoma, researchers at University of California, San Diego School of Medicine and Shiley Eye Institute turned to a mouse model of the disease.

12 Feb 2015

Study shows targeted therapeutic after chemotherapy kills transitional cancer cells

Timing may be decisive when it comes to overcoming cancer's ability to evade treatment. By hitting breast cancer cells with a targeted therapeutic immediately after chemotherapy, researchers from Brigham and Women's Hospital (BWH) were able to target cancer cells during a transitional stage when they were most vulnerable, killing cells and shrinking tumors in the lab and in pre-clinical models.

12 Feb 2015

Opioid withdrawal in Ontario newborns increases 15-fold

The number of newborns suffering from opioid withdrawal increased 15-fold in Ontario over 20 years, according to research published today in CMAJ Open.

12 Feb 2015

Researchers develop novel approach to identify potential antimalarial drugs

Each year nearly 600,000 people--mostly children under age five and pregnant women in sub-Saharan Africa--die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species--Plasmodium falciparum--has proven notoriously resistant to treatment efforts.

12 Feb 2015

Franziska Michor named winner of Creative Promise Prize in Biomedical Science

Franziska Michor was picked as the winner of a Creative Promise Prize in Biomedical Science for her research that fuses evolutionary biology, mathematics, and clinical research toward a better understanding of cancer genesis and treatments.

12 Feb 2015

UT Southwestern gets NCI grant to establish Heavy Ion Radiation Therapy Research Center in US

UT Southwestern Medical Center is leading a Texas consortium of researchers to establish the country's first National Center for Heavy Ion Radiation Therapy that could provide clinical care and research using heavy particles for innovative new cancer treatments.

12 Feb 2015

Cannabis Science highlights more attendees at the CFA African Healthcare Infrastructure Forum and Brainstorm

Cannabis Science, Inc., a U.S. Company specializing in cannabis formulation-based drug development and related consulting, highlights additional attendees at the CFA African Healthcare Infrastructure Forum and Brainstorm held at the African Union, in Washington DC, on February 6, 2015.

12 Feb 2015

FDA advisory committees to review Amgen's talimogene laherparepvec for metastatic melanoma treatment

Amgen announced today that the Cellular, Tissue and Gene Therapies Advisory Committee and the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration will jointly review the Company's Biologics License Application (BLA) for talimogene laherparepvec.

11 Feb 2015

Bayer launches new polycarbonate blend grade tailored for wearable medical devices

New grade offers high level of chemical resistance, excellent rigidity and toughness and limited biocompatibility compliance

11 Feb 2015

Cumberland initiates clinical development of Boxaban (ifetroban) oral capsule for AERD treatment

Cumberland Pharmaceuticals Inc. today announced an expansion of its pipeline with a new Phase II development program. The Company has initiated the clinical development of Boxaban (ifetroban) oral capsule for the treatment of aspirin-exacerbated respiratory disease (AERD).

11 Feb 2015

ADDF, Pfizer's CTI collaborate to advance development of new drugs for Alzheimer's disease

The Alzheimer's Drug Discovery Foundation and Pfizer's Centers for Therapeutic Innovation announced today a collaboration designed to advance the development of new small-molecule drugs for Alzheimer's disease and related dementias. As part of the first-of-its kind collaboration in Alzheimer's, the ADDF and CTI will jointly invest in translational research projects, with a focus on novel Alzheimer's drug targets.

11 Feb 2015

Synthetic DNA gel could bring researchers closer to printing artificial organs

A two-part water-based gel made of synthetic DNA and peptide could bring the inventors of a 3D bio printer closer to being able to print organs for transplant, or to replace animal testing. The teams led by Dongsheng Liu (Tsinghua University) and Will Shu (Heriot-Watt University) faced two main challenges: finding a matrix or scaffold to support the live cells in 3D, and being able to produce a consistent product which would not be rejected by transplant recipients.

11 Feb 2015

Oncolytics' REOLYSIN receives FDA Orphan Drug Designation for treatment of ovarian cancer

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of ovarian cancer.

11 Feb 2015

Researchers invent novel sock that can help prevent DVT, improve survival rates of patients

Patients who are bedridden or unable to move their legs are often at risk of developing Deep Vein Thrombosis (DVT), a potentially life-threatening condition caused by blood clots forming along the lower extremity veins of the legs. A team of researchers from the National University of Singapore's Yong Loo Lin School of Medicine and Faculty of Engineering has invented a novel sock that can help prevent DVT and improve survival rates of patients.

11 Feb 2015

UT Southwestern leads researchers to establish National Center for Heavy Ion Radiation Therapy

11 Feb 2015

Freiburg researchers identify novel approach to inhibit signalling processes in colorectal cancer cells

Colorectal carcinoma is the most frequent type of bowel cancer and the second most common tumour disease among men and women in Germany. So-called microsatellite stable colorectal cancer with mutations in the BRAF gene represents a particularly aggressive form.

11 Feb 2015

Psychemedics' revenue increases 4% to $6.8 million in fourth quarter 2014

Psychemedics Corporation today announced fourth quarter and year-end financial results for the period ended December 31, 2014. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of February 23, 2015 to be paid on March 6, 2015. This will be the Company's 74th consecutive quarterly dividend.

11 Feb 2015

UM one step closer to developing potential drug for treating brain cancer

Promentis Pharmaceuticals, Inc. recently announced it will enter an exclusive agreement with UM to commercialize a discovery made by a team of UM faculty scientists that has the potential to treat brain cancer and possibly other disorders of the central nervous system.

11 Feb 2015

Drugs News and Research

Lenvatinib therapy improves survival in patients with advanced radioiodine-refractory thyroid cancer

Specific combinations of therapies kill cancer cells, reduce tumors

Understanding the pattern of cellular changes that lead to retinal ganglion cell death in glaucoma

Study shows targeted therapeutic after chemotherapy kills transitional cancer cells

Opioid withdrawal in Ontario newborns increases 15-fold

Researchers develop novel approach to identify potential antimalarial drugs

Franziska Michor named winner of Creative Promise Prize in Biomedical Science

UT Southwestern gets NCI grant to establish Heavy Ion Radiation Therapy Research Center in US

Cannabis Science highlights more attendees at the CFA African Healthcare Infrastructure Forum and Brainstorm

FDA advisory committees to review Amgen's talimogene laherparepvec for metastatic melanoma treatment

Bayer launches new polycarbonate blend grade tailored for wearable medical devices

Cumberland initiates clinical development of Boxaban (ifetroban) oral capsule for AERD treatment

ADDF, Pfizer's CTI collaborate to advance development of new drugs for Alzheimer's disease

Synthetic DNA gel could bring researchers closer to printing artificial organs

Oncolytics' REOLYSIN receives FDA Orphan Drug Designation for treatment of ovarian cancer

Researchers invent novel sock that can help prevent DVT, improve survival rates of patients

UT Southwestern leads researchers to establish National Center for Heavy Ion Radiation Therapy

Freiburg researchers identify novel approach to inhibit signalling processes in colorectal cancer cells

Psychemedics' revenue increases 4% to $6.8 million in fourth quarter 2014

UM one step closer to developing potential drug for treating brain cancer

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News